Koninklijke Philips (PHIA) investor relations material

Strategic direction and growth ambitions

• Entering a new phase focused on profitable growth, targeting mid-single-digit sales CAGR and mid-teens margins by 2028, with €4.5–5 billion cumulative cash generation over the period.

• Strategy built on three pillars: focused value creation by segment, innovation growth leveraging AI and platforms, and disciplined execution with commercial excellence.

• Segment-specific strategies emphasize organic and inorganic investments, especially in Interventional and Monitoring platforms, with North America as a core growth engine.

• ESG ambitions for 2030 include improving 2.5 billion lives, significant emissions reductions, and embedding sustainability in business models.

• China and other growth markets remain long-term opportunities, with a disciplined approach to capital allocation and innovation tailored to local needs.

Innovation and platform leadership

• Accelerated innovation pipeline, including world-firsts in imaging (helium-free 3T MRI), AI-native interventional platforms (Azurion AI), and new care intelligence platforms in monitoring.

• Platform-based approach integrates hardware, software, data, and AI, leveraging a global installed base of 2.5 million systems and reaching 80% of top hospitals.

• Partnerships with leading clinical and technology organizations (e.g., Mayo Clinic, AWS, NVIDIA) drive co-creation and speed to market.

• AI and data orchestration are central to future growth, enabling personalized, efficient, and scalable care across hospital and home settings.

• Innovation expected to contribute 70–100 bps to growth acceleration, with commercial excellence adding 40–70 bps.

Financial framework and capital allocation

• Achieved 3.1% sales CAGR and expanded Adjusted EBITA margin from 7.4% in 2022 to 12.3% in 2025, with positive cash generation and a robust balance sheet.

• Targeting 3–4.5% sales growth in 2026, stepping up to mid-single-digit CAGR through 2028, with margin expansion from 12% to mid-teens.

• Free cash flow target of €1.3–1.5 billion in 2026 and €4.5–5 billion cumulatively, supported by productivity programs and working capital optimization.

• €1.5 billion new productivity program focused on cost competitiveness, lean central functions, and AI-driven efficiency.

• Capital allocation priorities: organic growth (R&D, CapEx), stable dividend (40–50% payout), selective M&A, and periodic share buybacks.